Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Identification of Two Novel Mutations in the CHM Gene Causing Choroideremia.

American journal of medical genetics. Part A·2026

Same author

PIKfyve is an essential component of the endolysosomal pathway within photoreceptors and the retinal pigment epithelium.

Experimental eye research·2026

Same author

RPE65 Variant p.(E519K) Causes a Novel Dominant Adult-Onset Maculopathy in 83 Affected Individuals.

Investigative ophthalmology & visual science·2025

Same author

RPE65 variant p.(E519K) causes a novel dominant adult-onset maculopathy in 83 affected individuals.

Research square·2025

Same author

Genetic Analysis of Choroideremia-Related Rab Escort Proteins.

International journal of molecular sciences·2025

Same author

Inferior sectoral chorioretinopathy in two patients with novel heterozygous <i>KIF11</i> mutations.

Ophthalmic genetics·2025

Same journal

Polymorphisms of Aldose Reductase (ALR2) Regulatory Gene are Risk Factors for Diabetic Retinopathy in Type-2 Diabetes Mellitus Patients in Bali, Indonesia.

The open ophthalmology journal·2018

Same journal

Maximising Refractive Outcomes with an Extended Depth of Focus IOL.

The open ophthalmology journal·2018

Same journal

Refractive Error among Male Primary School Students in Jazan, Saudi Arabia: Prevalence and Associated Factors.

The open ophthalmology journal·2018

Same journal

Outcomes of Wavefront-Optimized Laser-Assisted <i>In-Situ</i> Keratomileusis and Photorefractive Keratectomy for correction of Myopia and Myopic Astigmatism over One Year Follow-Up.

The open ophthalmology journal·2018

Same journal

Clinical Characteristics, Treatment Outcomes and Predictive Factors in Optic Neuritis.

The open ophthalmology journal·2018

Same journal

A New User-Friendly and Affordable Method in Descemet Stripping Endothelial Keratoplasty.

The open ophthalmology journal·2018

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Pharmacogenetics - getting closer.

Ian M Macdonald¹

¹Department of Ophthalmology, University of Alberta, Edmonton, AB, Canada.

The Open Ophthalmology Journal

|October 10, 2009

Summary

This summary is machine-generated.

Genetics advances in glaucoma care are explored, linking genetic discoveries with pharmacogenetics to enhance personalized medicine and improve patient treatment outcomes.

Keywords:

Pharmacogenetics genomics glaucoma personalized medicine.

Related Experiment Videos

Last Updated: Jun 19, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Area of Science:

Ophthalmology
Genetics
Pharmacology

Background:

Glaucoma is a leading cause of irreversible blindness worldwide.
Understanding the genetic basis of glaucoma is crucial for developing targeted therapies.
Personalized medicine approaches are transforming patient care across various diseases.

Purpose of the Study:

To review the application of genetic discoveries in glaucoma patient care.
To explain the principles of pharmacogenetics in the context of glaucoma.
To highlight the potential of integrating genetic insights into personalized glaucoma treatment strategies.

Main Methods:

Literature review of genetic studies in glaucoma.
Analysis of pharmacogenetic data relevant to glaucoma.
Synthesis of current understanding of glaucoma genetics and personalized medicine.

Main Results:

Genetic factors significantly contribute to glaucoma development and progression.
Pharmacogenetics offers potential for tailoring glaucoma medications based on individual genetic profiles.
Personalized medicine, guided by genetic insights, promises improved therapeutic efficacy and reduced adverse events in glaucoma management.

Conclusions:

Genetic advancements are pivotal for personalized glaucoma care.
Pharmacogenetics provides a framework for optimizing glaucoma treatment.
Integrating genetic and pharmacogenetic knowledge will advance patient outcomes in glaucoma.